Healthcare News | BioTuesdays by Kilmer Lucas IR

Markets

WB starts VistaGen Therapeutics at OP; fair value estimate $7

William Blair launched coverage of VistaGen Therapeutics (NASDAQ:VTGN) with an “outperform” rating and fair value estimate of $7. The stock closed at 60 cents on Aug. 27. VistaGen Therapeutics is focused on developing...

August 28, 2019

Developments

Zenabis outperforms cannabis design capacity by 46% in July

Zenabis Global’s (TSX:ZENA) cultivation output in July 2019 was 1,238 kg of dried cannabis, which represents a 46.2% outperformance relative to original design capacity and a 12.9% outperformance relative to revised...

August 28, 2019

Markets

Stifel starts Cerus at buy; PT $7

Stifel initiated coverage of Cerus (NASDAQ:CERS) with a “buy” rating and $7 price target. The stock closed at $5.21 on Aug. 27. “Over time, we see significant potential upside as the company executes against its high...

August 28, 2019

Executive Moves

Zegbeh Jallah joins Roth heath care research team

Roth Capital Partners named Zegbeh Jallah as a director and research analyst covering biotechnology. Her research coverage is expected to include SMID cap biotech companies across the therapeutic space, with an initial...

August 27, 2019

Developments

Zenabis inks agreement for cannabis-infused beverage inputs

Zenabis Global (TSX:ZENA) has secured a supply of cannabis-infused inputs for the production of cannabis-infused beverages and other products. Under the accord, Zenabis will provide cannabis to anunnamed beverage...

August 27, 2019

Developments

iBio and CC-Pharming expand biopharma business collaboration in China

iBio (NYSE AMERICAN:IBIO) granted partner CC-Pharming an exclusive, royalty-bearing commercial license to iBio’s bio-better rituximab product candidates in China.

August 27, 2019

Markets

Raymond James starts Profound Medical at OP; PT $4

Raymond James initiated coverage of Profound Medical (TSX:PRN; OTCQX:PRFMF) with an “outperform” rating and price target of $4. The stock closed at 92 cents on Aug. 23. “With its highly experienced management team...

August 26, 2019

Markets

Dawson James starts Fortress Biotech at buy; PT $19

Dawson James Securities launched coverage of Fortress Biotech (NASDAQ:FBIO) with a “buy” rating and price target of $19. The stock closed at $6.51 on Aug. 23. “Creating a launch pad for biotechnology assets, Fortress...

August 26, 2019

Markets

HCW starts Sangamo Therapeutics at buy; PT $16

H.C. Wainwright initiated coverage of Sangamo Therapeutics (NASDAQ:SGMO) with a “buy” rating and $16 price target. The stock closed at $11.02 on Aug. 23. Analyst Debjit Chattopadhyay writes that the prevailing view on...

August 26, 2019

Markets

Dawson James starts Athersys at buy; PT $11

Dawson James Securities launched coverage of Athersys (NASDAQ:ATHX) with a “buy” rating and $11 price target. The stock closed at $1.40 on Aug. 23. “Athersys has the potential to change the treatment paradigm for...

August 26, 2019

Developments

Satsuma Pharma doses first patient in Phase 3 migraine trial

Closely-held Satsuma Pharmaceuticals dosed the first patient in its Phase 3 efficacy trial of STS101 for the acute treatment of migraine. STS101 is a drug-device combination of dihydroergotamine mesylate (DHE) dry...

August 23, 2019

Developments

BeyondSpring’s Plinabulin demonstrates superior quality of life for prevention of neutropenia

BeyondSpring (NASDAQ: BYSI) plans to present positive data in an abstract titled, “Quality of Life (QoL) in Advanced NSCLC Patients Treated with Docetaxel and with Either Plinabulin or Pegfilgrastim for the Prevention...

August 23, 2019

Zenabis outperforms cannabis design capacity by 46% in July

Stifel starts Cerus at buy; PT $7

Zegbeh Jallah joins Roth heath care research team

Zenabis inks agreement for cannabis-infused beverage inputs

iBio and CC-Pharming expand biopharma business collaboration in China

Raymond James starts Profound Medical at OP; PT $4

Dawson James starts Fortress Biotech at buy; PT $19

HCW starts Sangamo Therapeutics at buy; PT $16

Dawson James starts Athersys at buy; PT $11

Satsuma Pharma doses first patient in Phase 3 migraine trial

BeyondSpring’s Plinabulin demonstrates superior quality of life for prevention of neutropenia

General

More